Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro and Zepbound approvals in 2022 and 2023 gave the lowest returns, despite these drugs generating billions in revenue. This shows that investing during market fear or before hype can lead to much higher gains than buying at peak optimism. Future growth from new drugs like retatrutide will be key to justifying current high valuations.
Eli Lilly's stock on Pluang trades at USD 1,165.65 as of Oct 07, 2026 19:12 WIB, closer to its 52-week high of $1.28K than its low of $799.57, showing resilience despite past hype-driven entry points yielding lower returns. The stock's 1-day gain of 0.70% contrasts with the mixed investor sentiment reflected in a 55% sell and 45% buy order split. This positioning highlights how current market dynamics differ from the peaks of optimism around Mounjaro and Zepbound approvals.
Eli Lilly (LLY) is recommended as a Strong Buy due to its attractive valuation and role as a diversification play for portfolios heavily invested in AI. Trading at about 24 times its 2027 earnings estimates, the stock is seen as premium but not overp...
Eli Lilly's stock is predicted to rise nearly 19% over the next year, driven by rapid growth in its oncology, immunology, and neuroscience drug portfolios, which grew 121% year-over-year last quarter. While known for weight loss drugs like Mounjaro a...
Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. ...
The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is ...
